|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.35 USD | +43.84% |
|
+39.47% | +46.41% |
ImmunityBio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 0.622 million compared to USD 0.24 million a year ago. Net loss was USD 583.2 million compared to USD 416.57 million a year ago.
Basic loss per share from continuing operations was USD 1.15 compared to USD 1.04 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +46.41% | 4.98B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
IMMUNITYBIO, INC. 
